TNFRSF4 and atopic eczema: Moreover, epitope binning analyses show that they recognize distinct epitopes not overlapping with that of the only FDA-approved Rocatinlimab to treat atopic dermatitis, thus providing new tools to target OX-40 with different biological properties (11).